These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 7535842)

  • 1. Clinical applications of hematopoietic growth factors.
    Vose JM; Armitage JO
    J Clin Oncol; 1995 Apr; 13(4):1023-35. PubMed ID: 7535842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of hematopoietic growth factors in the treatment of acute leukemia.
    Bradstock KF
    Curr Pharm Des; 2002; 8(5):343-55. PubMed ID: 12069373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
    Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
    J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical application of hematopoietic growth factor (IL-3, G-CSF, GM-CSF, and EPO)].
    Motoyoshi K
    Nihon Rinsho; 1992 Aug; 50(8):1967-72. PubMed ID: 1279240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors.
    Siena S; Bregni M; Bonsi L; Sklenar I; Bagnara GP; Bonadonna G; Gianni AM
    Exp Hematol; 1993 Nov; 21(12):1583-90. PubMed ID: 7691640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
    Vadhan-Raj S
    Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321.
    Anderson JE; Appelbaum FR
    Curr Opin Hematol; 1994 May; 1(3):203-9. PubMed ID: 9371283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro enhancement of erythropoiesis by steel factor in Diamond-Blackfan anemia and treatment of other congenital cytopenias with recombinant interleukin 3/granulocyte-macrophage colony stimulating factor.
    Sieff C; Guinan E
    Stem Cells; 1993 Jul; 11 Suppl 2():113-22. PubMed ID: 7691316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of hematopoietic growth factors in marrow transplantation.
    Nemunaitis J
    Curr Opin Oncol; 1994 Mar; 6(2):139-45. PubMed ID: 7516712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
    Lemoli RM; Gulati SC
    Stem Cells; 1993 Sep; 11(5):435-44. PubMed ID: 7694721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status of the clinical application of hematopoietic growth factors in oncology].
    Karthaus M; Ganser A
    Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical toxicity of cytokines used as haemopoietic growth factors.
    Vial T; Descotes J
    Drug Saf; 1995 Dec; 13(6):371-406. PubMed ID: 8652081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human hematopoietic growth factors: old lessons and new perspectives.
    Dempke W; Von Poblozki A; Grothey A; Schmoll HJ
    Anticancer Res; 2000; 20(6D):5155-64. PubMed ID: 11326688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
    Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
    Vadhan-Raj S; Papadopoulos NE; Burgess MA; Linke KA; Patel SR; Hays C; Arcenas A; Plager C; Kudelka AP; Hittelman WN
    J Clin Oncol; 1994 Apr; 12(4):715-24. PubMed ID: 8151315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use and toxicity of the colony-stimulating factors.
    Schriber JR; Negrin RS
    Drug Saf; 1993 Jun; 8(6):457-68. PubMed ID: 7687134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in vitro effects of stem cell factor and PIXY321 on myeloid progenitor formation (CFU-GM) from immunomagnetic separated CD34+ cord blood.
    Cairo MS; Law P; van de Ven C; Plunkett JM; Williams D; Ishizawa L; Gee A
    Pediatr Res; 1992 Sep; 32(3):277-81. PubMed ID: 1383918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic use of hematopoietic growth factors.
    Costa JJ
    J Allergy Clin Immunol; 1998 Jan; 101(1 Pt 1):1-6. PubMed ID: 9449493
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of hematopoietic growth factors in the treatment of neoplastic diseases.
    St Onge J; Jacobson RJ
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):53-63. PubMed ID: 1380737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.